This document discusses gastrointestinal diseases that are more prevalent in obese women compared to men. It notes that obesity is associated with higher risks of GERD, NAFLD, and gallstones in women. Some key differences between women and men are discussed, such as the protective effects of female sex hormones against NAFLD before menopause. Modest weight loss through diet and lifestyle changes can help treat obesity-related gastrointestinal conditions by reducing fat deposits and abnormal liver enzymes.
Irritable Bowel Syndrome Part 1 - Dr Vivek BaligaDr Vivek Baliga
In this presentation, Dr Vivek Baliga discusses the important aspects of irritable bowel syndrome - a common medical problem in clinical practice. For more articles, visit http://baligadiagnostics.com/author/drbvb/
Irritable bowel syndrome (IBS) is a group of symptoms, including pain discomfort in your abdomen combined with changes in your bowel movement patterns.
For More detail visit this link:
http://goo.gl/RaZhvc
Irritable Bowel Syndrome Part 1 - Dr Vivek BaligaDr Vivek Baliga
In this presentation, Dr Vivek Baliga discusses the important aspects of irritable bowel syndrome - a common medical problem in clinical practice. For more articles, visit http://baligadiagnostics.com/author/drbvb/
Irritable bowel syndrome (IBS) is a group of symptoms, including pain discomfort in your abdomen combined with changes in your bowel movement patterns.
For More detail visit this link:
http://goo.gl/RaZhvc
Functional Digestive Disorders and the Role of Diet by Giovanni BarbaraKiwifruit Symposium
Prof. Giovanni Barbara, Professor of Medicine and Gastroenterology at the University of Bologna, Italy: http://www.kiwifruitsymposium.org/presentations/functional-gastrointestinal-disorders-and-the-role-of-diet/
Roughly 30% of the population is affected by at least one of the several functional gastrointestinal disorders (FGIDs) with functional dyspepsia, irritable bowel syndrome (IBS) and chronic constipation (CC) being the most common.
My Knee Hurts! A Look at Joint Pain in Children - Marla Guzman, MD - 1.12.2021Summit Health
Is your child complaining of joint pain? Learn about concerning symptoms and when to seek medical advice. Our expert discusses the various causes of joint pains in children, how a pediatric rheumatologist evaluates musculoskeletal complaints, and available treatment options.
IRRITABLE BOWEL SYNDROME
The term irritable bowel syndrome is used to describe a functional gastrointestinal disorder characterized by a variable combination of chronic and recurrent intestinal symptoms not explained by structural or biochemical abnormalities.
Functional Digestive Disorders and the Role of Diet by Giovanni BarbaraKiwifruit Symposium
Prof. Giovanni Barbara, Professor of Medicine and Gastroenterology at the University of Bologna, Italy: http://www.kiwifruitsymposium.org/presentations/functional-gastrointestinal-disorders-and-the-role-of-diet/
Roughly 30% of the population is affected by at least one of the several functional gastrointestinal disorders (FGIDs) with functional dyspepsia, irritable bowel syndrome (IBS) and chronic constipation (CC) being the most common.
My Knee Hurts! A Look at Joint Pain in Children - Marla Guzman, MD - 1.12.2021Summit Health
Is your child complaining of joint pain? Learn about concerning symptoms and when to seek medical advice. Our expert discusses the various causes of joint pains in children, how a pediatric rheumatologist evaluates musculoskeletal complaints, and available treatment options.
IRRITABLE BOWEL SYNDROME
The term irritable bowel syndrome is used to describe a functional gastrointestinal disorder characterized by a variable combination of chronic and recurrent intestinal symptoms not explained by structural or biochemical abnormalities.
OSA is an entity that is increasingly being managed by otolaryngologists...Hope this presentation helps to clear any doubts regarding its diagnosis and management!
Adipose tissue as an endocrine organ:
Adipose tissue has been recognized as the quantitatively most important energy store of the human body for many years, in addition to its functions as mechanical and thermal insulator. During the last 10 years, adipose tissue has come into focus as an endocrine organ important for development of many diseases related to obesity including insulin resistance, type 2 diabetes, dyslipidemia, hypertension and cardiovascular disease. Adipose tissue secretes a variety of bioactive peptides that play important roles in insulin action, energy homeostasis, inflammation, and cell growth. These secretory proteins from the adipose organ are named adipokines and have many physiological effects on different organs including the brain, bone, reproductive organs, liver, skeletal muscles, immune cells and blood vessels. Adipokines may locally regulate fat mass by modulating adipocyte size/number or angiogenesis and inversely increased fat mass leads to dysregulation of adipocyte functions.
If you’re a 40-something woman, you probably have given hormone replacement therapy (HRT) at least a passing thought. Treatments have evolved over the years and become more effective. https://labelleviemedicalcare.com/estrogen-and-your-health/
Does the diabetes presentations and treatment differs in the different stages of women's life. What is the interplay between diabetes and both puberty and menopause
Dr Pravin John and Dr John Thanakumar, Anurag Hospital, Coimbatore present the differences between metabolic and obesity surgery - dept of advanced laparoscopy and obesity
the world wide pandemic of obesity is associated with different types of fertility implications. Obesity is widely prevalent in western countries but it is also affecting the poor and developing counties as well. Femal fertilty is affected by increasing PCOS and other pregnancy related complications. Adipokines are of abnormal value in thise women affecting ovulation Oocyte quality , fertilization etc. The chance of pregnancy complications in early trimester as well as late trimester in the form of pregnancy loss , hypertension Diabetes . increased incidence of opeerative delivery are increasing. The baby born to the obese women are also associated with increased morbidity. Male reproduction is also affected by various ways mainly physical and endrocrinological. Semen parameters are usually abnormal in obese men. Oloigoasthenospermia is an usual finding in obese subfertile men . Sexual activity is also seem to be reduced in both obese male and female .
The treatment of obesity is mainly by changes in lifestyle modifications . Some of the patients need pharmaco therapy like Orlistat, metformin etc approved by FDA. The who are morbidly obese might require Bariatic surgery though it is not the first line therapy. In conclusion one must remember the preventive steps
PCOS- An insight into polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is extremely prevalent and probably constitutes the most frequently encountered endocrine (hormone) disorder in women of reproductive age
Fight against polycystic ovary syndrome problems (pcos pcod)furocyst01
It may cause issues with your intervals and make it hard to become pregnant. PCOS can also cause undesirable changes in how you look. When it is not treated, over the years it may result in other health issues, like diabetes and cardiovascular disease. Most women with Polycystic Ovary Syndrome Problems develop many tiny cysts in their ovaries. That’s why it’s known as PCOS. The cysts aren’t dangerous but contribute to hormone imbalances. Early identification and treatment can help control the symptoms and avoid long-term issues.
PCOS IS THE THIEF OF WOMENHOOD........an enigmatic condition must be understood and managed according to the age it presents.......contact dr jaideep at jaideep malhotraagra@gmail.com for CME AND WORKSHOPS IN YOUR CITY
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
1. Kurdistan Board GEH/GIT SurgeryKurdistan Board GEH/GIT Surgery
Weekly J ClubWeekly J Club
Supervised by:Supervised by:
Dr. Mohamed AlshekhaniDr. Mohamed Alshekhani
2. Introduction:Introduction:
Obesity is a well-known, chronic condition affects all ages.Obesity is a well-known, chronic condition affects all ages.
The obesity epidemic has significant impact from social stigma toThe obesity epidemic has significant impact from social stigma to
costly, comorbid diseases.costly, comorbid diseases.
Gender differences exist between women & men as omen are moreGender differences exist between women & men as omen are more
likely:likely:
(1) Dissatisfied with their weight.(1) Dissatisfied with their weight.
(2) Dissatisfied with their body.(2) Dissatisfied with their body.
(3) Associate body image with self-esteem.(3) Associate body image with self-esteem.
3. Epidemiology:Epidemiology:
The prevalence is similar in women &men, with 1/3 adults beingThe prevalence is similar in women &men, with 1/3 adults being
obese.obese.
Gender diff in the prevalence occur in certain subpopulations,non-Gender diff in the prevalence occur in certain subpopulations,non-
Hispanic African American women ,older women (age >60)Hispanic African American women ,older women (age >60)
More severe forms of obesity affect women more than men.More severe forms of obesity affect women more than men.
4. GIT Diseases in obese women:GERDGIT Diseases in obese women:GERD
Obesity is a known risk factor for GERD.Obesity is a known risk factor for GERD.
Similar prevalence of symptomatic GERD in women & men.Similar prevalence of symptomatic GERD in women & men.
GERD complications;erosive esophagitis,Barrett & EAC, are lessGERD complications;erosive esophagitis,Barrett & EAC, are less
common incommon in women.women.
Central adiposity is less common in women than men, may explainCentral adiposity is less common in women than men, may explain
the lower complications in women.the lower complications in women.
Sex hormones implicated to explain different GERD manifestations.Sex hormones implicated to explain different GERD manifestations.
Medical management, including behavioral modifications & acidMedical management, including behavioral modifications & acid
suppressive, is effective in ameliorating GERD symptoms.suppressive, is effective in ameliorating GERD symptoms.
Weight loss resulting from surgical or diet/lifestyle interventionsWeight loss resulting from surgical or diet/lifestyle interventions
can reduce or eliminate the symptoms of GERD:can reduce or eliminate the symptoms of GERD:
(1) Dose-response relation between wt loss & symptoms(1) Dose-response relation between wt loss & symptoms
resolution.resolution.
(2) Women derive benefit from smaller amounts of weight loss(2) Women derive benefit from smaller amounts of weight loss
5. GIT Diseases in obese women:NAFLDGIT Diseases in obese women:NAFLD
Strong correlations between NAFLD / obesity in women.Strong correlations between NAFLD / obesity in women.
Prevalence of NAFLD is similar in women & men.Prevalence of NAFLD is similar in women & men.
NAFLD is less common in premenopausal women versus age-NAFLD is less common in premenopausal women versus age-
matched men.matched men.
Sex hormones are also linked to obesity / NAFLD.Sex hormones are also linked to obesity / NAFLD.
Perimenopausal / postmenopausal women have lower estrogen &Perimenopausal / postmenopausal women have lower estrogen &
increased androgens, favors the development of the metabolicincreased androgens, favors the development of the metabolic
syndrome and NAFLD via increased visceral fat deposition.syndrome and NAFLD via increased visceral fat deposition.
The suggested protective effect of female sex hormonesThe suggested protective effect of female sex hormones
(1) Alower prevalence of NAFLD in premenopausal women(1) Alower prevalence of NAFLD in premenopausal women
compared with men of the same agecompared with men of the same age
(2) Women with NAFLD have significantly lower estradiol compared(2) Women with NAFLD have significantly lower estradiol compared
with those without NAFLD.with those without NAFLD.
(3) Women >50 have a higher prevalence of NAFLD(3) Women >50 have a higher prevalence of NAFLD
6. GIT Diseases in obese women:NAFLDGIT Diseases in obese women:NAFLD
Weight loss is typically recommended for obese patients withWeight loss is typically recommended for obese patients with
NAFLD; but effect on the natural history of the disease is unclear.NAFLD; but effect on the natural history of the disease is unclear.
Modest weight loss of 5-10% or more can correct abnormal liverModest weight loss of 5-10% or more can correct abnormal liver
chemistries&decrease liver size, fat content &steatohepatitis.chemistries&decrease liver size, fat content &steatohepatitis.
Rapid weight loss after gastric bypass surgery, very-low-calorieRapid weight loss after gastric bypass surgery, very-low-calorie
diets, or prolonged fasting,lowers hepatic fat content but candiets, or prolonged fasting,lowers hepatic fat content but can
induce hepatic inflammation, worsening steatohepatitis,so slow,induce hepatic inflammation, worsening steatohepatitis,so slow,
gradual weight loss is essential.gradual weight loss is essential.
NAFLD in women is also linked to DM, MS, low estrogen &elevatedNAFLD in women is also linked to DM, MS, low estrogen &elevated
androgen.androgen.
Premenopausal women have a lower prevalence of NAFLD, likelyPremenopausal women have a lower prevalence of NAFLD, likely
due to the protective effect of estrogen.due to the protective effect of estrogen.
Effective trt of NAFLD includes slow, gradual weight loss.Effective trt of NAFLD includes slow, gradual weight loss.
7. GIT Diseases in obese women:ObesityGIT Diseases in obese women:Obesity
Obesity increase the prevalence of GSs in women specially inObesity increase the prevalence of GSs in women specially in
child-bearing age.child-bearing age.
Parity further increase the risk.Parity further increase the risk.
HRT increase the risk.HRT increase the risk.
Ocs (not low estrogen) increase the risk.Ocs (not low estrogen) increase the risk.
URSO effective at preventing gallstone formation inURSO effective at preventing gallstone formation in obese women.obese women.
Editor's Notes
Irritable Bowel Syndrome Slide Cover
IBS was long dismissed as a psychosomatic condition.1 It has no clear etiology or pathophysiology, affects mainly women, and is not fatal.2
However, attitudes are changing as physicians learn more about the pathophysiology of IBS.
The incidence and prevalence of IBS have not been extensively monitored, so it is difficult to discern historical trends. Also, only a small proportion of IBS sufferers seek treatment,3 and diagnosis of the condition is difficult.4
References:
1.Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet. December 1997;350:1691-1695.
2. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. August 1990;99:409-415.
3. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. June 1992;116(pt 1):1009-1016.
4. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J. July 1999;161:154-160.
IBS was long dismissed as a psychosomatic condition.1 It has no clear etiology or pathophysiology, affects mainly women, and is not fatal.2
However, attitudes are changing as physicians learn more about the pathophysiology of IBS.
The incidence and prevalence of IBS have not been extensively monitored, so it is difficult to discern historical trends. Also, only a small proportion of IBS sufferers seek treatment,3 and diagnosis of the condition is difficult.4
References:
1.Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet. December 1997;350:1691-1695.
2. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. August 1990;99:409-415.
3. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. June 1992;116(pt 1):1009-1016.
4. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J. July 1999;161:154-160.
IBS was long dismissed as a psychosomatic condition.1 It has no clear etiology or pathophysiology, affects mainly women, and is not fatal.2
However, attitudes are changing as physicians learn more about the pathophysiology of IBS.
The incidence and prevalence of IBS have not been extensively monitored, so it is difficult to discern historical trends. Also, only a small proportion of IBS sufferers seek treatment,3 and diagnosis of the condition is difficult.4
References:
1.Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet. December 1997;350:1691-1695.
2. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. August 1990;99:409-415.
3. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. June 1992;116(pt 1):1009-1016.
4. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J. July 1999;161:154-160.
IBS was long dismissed as a psychosomatic condition.1 It has no clear etiology or pathophysiology, affects mainly women, and is not fatal.2
However, attitudes are changing as physicians learn more about the pathophysiology of IBS.
The incidence and prevalence of IBS have not been extensively monitored, so it is difficult to discern historical trends. Also, only a small proportion of IBS sufferers seek treatment,3 and diagnosis of the condition is difficult.4
References:
1.Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet. December 1997;350:1691-1695.
2. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. August 1990;99:409-415.
3. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. June 1992;116(pt 1):1009-1016.
4. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J. July 1999;161:154-160.
IBS was long dismissed as a psychosomatic condition.1 It has no clear etiology or pathophysiology, affects mainly women, and is not fatal.2
However, attitudes are changing as physicians learn more about the pathophysiology of IBS.
The incidence and prevalence of IBS have not been extensively monitored, so it is difficult to discern historical trends. Also, only a small proportion of IBS sufferers seek treatment,3 and diagnosis of the condition is difficult.4
References:
1.Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet. December 1997;350:1691-1695.
2. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. August 1990;99:409-415.
3. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. June 1992;116(pt 1):1009-1016.
4. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J. July 1999;161:154-160.
IBS was long dismissed as a psychosomatic condition.1 It has no clear etiology or pathophysiology, affects mainly women, and is not fatal.2
However, attitudes are changing as physicians learn more about the pathophysiology of IBS.
The incidence and prevalence of IBS have not been extensively monitored, so it is difficult to discern historical trends. Also, only a small proportion of IBS sufferers seek treatment,3 and diagnosis of the condition is difficult.4
References:
1.Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet. December 1997;350:1691-1695.
2. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. August 1990;99:409-415.
3. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. June 1992;116(pt 1):1009-1016.
4. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J. July 1999;161:154-160.
IBS is one of over 20 functional gastrointestinal (GI) disorders.1 The functional GI disorders vary clinically and are characterized by chronic or recurrent symptoms not explained by structural or biochemical abnormalities. It appears that these disorders relate to abnormalities in motility and/or afferent sensitivity as modulated by the central nervous system.2
IBS is defined as a functional bowel disorder in which abdominal pain is associated with a change in bowel habit with features of disordered defecation.3
Features of disordered defecation include3
Urgency
Altered stool consistency
Altered stool frequency
Incomplete evacuation
References:
1. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int. December 1990;3:159-172.
2. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther. 1999;13(suppl 2):3-14.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):1143-1147.
IBS is one of over 20 functional gastrointestinal (GI) disorders.1 The functional GI disorders vary clinically and are characterized by chronic or recurrent symptoms not explained by structural or biochemical abnormalities. It appears that these disorders relate to abnormalities in motility and/or afferent sensitivity as modulated by the central nervous system.2
IBS is defined as a functional bowel disorder in which abdominal pain is associated with a change in bowel habit with features of disordered defecation.3
Features of disordered defecation include3
Urgency
Altered stool consistency
Altered stool frequency
Incomplete evacuation
References:
1. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int. December 1990;3:159-172.
2. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther. 1999;13(suppl 2):3-14.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):1143-1147.
IBS is one of over 20 functional gastrointestinal (GI) disorders.1 The functional GI disorders vary clinically and are characterized by chronic or recurrent symptoms not explained by structural or biochemical abnormalities. It appears that these disorders relate to abnormalities in motility and/or afferent sensitivity as modulated by the central nervous system.2
IBS is defined as a functional bowel disorder in which abdominal pain is associated with a change in bowel habit with features of disordered defecation.3
Features of disordered defecation include3
Urgency
Altered stool consistency
Altered stool frequency
Incomplete evacuation
References:
1. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int. December 1990;3:159-172.
2. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther. 1999;13(suppl 2):3-14.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):1143-1147.
IBS is one of over 20 functional gastrointestinal (GI) disorders.1 The functional GI disorders vary clinically and are characterized by chronic or recurrent symptoms not explained by structural or biochemical abnormalities. It appears that these disorders relate to abnormalities in motility and/or afferent sensitivity as modulated by the central nervous system.2
IBS is defined as a functional bowel disorder in which abdominal pain is associated with a change in bowel habit with features of disordered defecation.3
Features of disordered defecation include3
Urgency
Altered stool consistency
Altered stool frequency
Incomplete evacuation
References:
1. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int. December 1990;3:159-172.
2. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther. 1999;13(suppl 2):3-14.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):1143-1147.